Get the Stockscreener App
0.5195
2.99%
0.0151
After Hours:
.52
0.0005
+0.10%
Bluebird Bio Inc stock is traded at $0.5195, with a volume of 6.35M.
It is up +2.99% in the last 24 hours and down -7.48% over the past month.
bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.
See More
Previous Close:
$0.5044
Open:
$0.51
24h Volume:
6.35M
Relative Volume:
0.86
Market Cap:
$99.15M
Revenue:
$21.73M
Net Income/Loss:
$-91.17M
P/E Ratio:
-0.5093
EPS:
-1.02
Net Cash Flow:
$-286.43M
1W Performance:
+6.26%
1M Performance:
-7.48%
6M Performance:
-59.41%
1Y Performance:
-82.91%
1-Day Range:
$0.505
$0.5407
1-Week Range:
$0.4704
$0.5414
52-Week Range:
$0.4575
$5.53
Bluebird Bio Inc Stock (BLUE) Company Profile
Name
Bluebird Bio Inc
Sector
Industry
Phone
339-499-9300
Address
455 GRAND UNION BOULEVARD, SOMERVILLE, MA
Bluebird Bio Inc Stock (BLUE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-28-23 | Initiated | JP Morgan | Overweight |
| Mar-07-23 | Initiated | Robert W. Baird | Outperform |
| Aug-05-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-02-22 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Apr-06-22 | Downgrade | Cowen | Outperform → Market Perform |
| Mar-07-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Nov-08-21 | Reiterated | Barclays | Equal Weight |
| Nov-08-21 | Reiterated | Canaccord Genuity | Hold |
| Nov-08-21 | Downgrade | Goldman | Neutral → Sell |
| Nov-08-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-08-21 | Reiterated | RBC Capital Mkts | Sector Perform |
| Nov-08-21 | Reiterated | Wedbush | Neutral |
| Nov-08-21 | Reiterated | Wells Fargo | Equal Weight |
| Aug-10-21 | Downgrade | Canaccord Genuity | Buy → Hold |
| Aug-10-21 | Downgrade | Goldman | Buy → Neutral |
| Aug-10-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Aug-10-21 | Resumed | William Blair | Mkt Perform |
| Aug-09-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-01-21 | Downgrade | Berenberg | Buy → Hold |
| Mar-10-21 | Upgrade | Mizuho | Neutral → Buy |
| Feb-17-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-16-21 | Downgrade | BofA Securities | Buy → Neutral |
| Feb-16-21 | Downgrade | Wedbush | Outperform → Neutral |
| Feb-16-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Dec-09-20 | Downgrade | Maxim Group | Buy → Hold |
| Nov-11-20 | Initiated | Berenberg | Buy |
| Nov-05-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Nov-05-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Nov-05-20 | Downgrade | Stifel | Buy → Hold |
| Nov-02-20 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-20-20 | Initiated | Mizuho | Buy |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| Mar-27-20 | Upgrade | Stifel | Hold → Buy |
| Feb-19-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Feb-03-20 | Resumed | BofA/Merrill | Buy |
| Feb-03-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-13-19 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Nov-19-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-04-19 | Upgrade | Wedbush | Neutral → Outperform |
| Oct-01-19 | Initiated | Stifel | Hold |
| Aug-12-19 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-18-19 | Upgrade | Maxim Group | Hold → Buy |
View All
Bluebird Bio Inc Stock (BLUE) Latest News
Bluebird bio to cut 25% of jobs in fresh bid to battle cash crunch - AOL
bluebird bio Announces Completion of its Q2 2024 Form 10-Q Filing - StockTitan
Bluebird: Q2 Earnings Snapshot - San Antonio Express-News
Bluebird: Q2 Earnings Snapshot - San Francisco Chronicle
Bluebird: Q2 Earnings Snapshot - Darien Times
Bluebird: Q2 Earnings Snapshot - Marketscreener.com
bluebird bio Announces Completion of its Q2 2024 Form 10-Q Filing - Business Wire
bluebird bio Announces Completion of its Q2 2024 Form 10-Q Filing - The Bakersfield Californian
Wall Street SWOT: Bluebird Bio stock faces headwinds amid gene therapy push - Investing.com
Leerink Partnrs Weighs in on bluebird bio, Inc.'s Q2 2024 Earnings (NASDAQ:BLUE) - MarketBeat
bluebird bio (NASDAQ:BLUE) Research Coverage Started at StockNews.com - MarketBeat
bluebird bio: Scientific Success And Financial Success, And The Gap Between - Seeking Alpha
Pfizer’s Strategy Looks Shakier After Sickle-Cell Drug Disappointment - Barron's
Bluebird bio to cut 25% of workforce as part of restructuring - MSN
Leerink Partnrs Comments on bluebird bio, Inc.'s Q4 2025 Earnings (NASDAQ:BLUE) - MarketBeat
bluebird bio (NASDAQ:BLUE) Price Target Lowered to $2.00 at Wells Fargo & Company - MarketBeat
The Analyst Verdict: bluebird bio In The Eyes Of 5 Experts - Benzinga
bluebird bio to cut workforce by about 25% - MSN
Five things: Kairos Shen, bluebird layoffs, UMass fundraising, green tomatoes and white eggplants - The Business Journals
bluebird lets go staff amid financial struggle - The Pharma Letter
Layoff Tracker: Bluebird Bio to Cut 25% of Workforce and More News - BioSpace
Gene Therapy-Focused Bluebird Bio Restructures, Cuts Is Workforce By 25%, Seeks To Breakeven Next Year - AOL
Bluebird Bio Restructures To Optimize Cost Structure And Extend Cash Runway - Contract Pharma
Bluebird Bio, a gene therapy company, is laying off 25% of its workers to cut costs - STAT
Bluebird to lay off another 25% of workforce in latest restructuring - BioPharma Dive
Gene Therapy-Focused Bluebird Bio Restructures, Cuts Is Workforce By 25%, Seeks To Breakeven Next Year - Yahoo Finance
Bluebird Bio is laying off 25 percent of its workers to cut costs - The Boston Globe
bluebird bio announces restructuring to cut costs By Investing.com - Investing.com Canada
Bluebird Bio to Lay Off 25% of Workforce - BioSpace
Bluebird bio lays off 25% of workforce as gene therapy pioneer struggles to stay afloat - FiercePharma
Bluebird bio to cut 25% of jobs in fresh bid to battle cash crunch - Reuters
bluebird bio announces restructuring to cut costs - Investing.com India
Novo’s CEO is in the hot seat today - STAT
Bluebird Bio to Cut 25% of Staff Amid Gene Therapy Struggles - BNN Bloomberg
Somerville gene therapy company cutting nearly 100 jobs - NBC Boston
bluebird bio to undergo more layoffs - The Business Journals
bluebird bio Initiates Restructuring Intended to Optimize Cost Structure and Enable Quarterly Cash Flow Break-Even in the Second Half of 2025 - BioSpace
Bluebird bio gains after cutting 25% workforce to reduce costs - XM
Bluebird Bio Announces Restructuring and Targets Break-Even - TipRanks
bluebird bio announces restructuring to cut costs - Investing.com
Bluebird bio to Cut 25% of Workforce in Restructuring - MarketWatch
bluebird bio to cut workforce by about 25% (NASDAQ:BLUE) - Seeking Alpha
Bluebird Bio To Reduce Approx. 25% Of Its WorkforceQuick Facts - Nasdaq
bluebird bio Initiates Restructuring Intended to Optimize Cost Structure and Enable Quarterly Cash Flow Break-Even in the Second Half of 2025 - StockTitan
Bluebird bio stock plunges to 52-week low at $0.48 By Investing.com - Investing.com Canada
Bluebird bio stock plunges to 52-week low at $0.48 - Investing.com
Cell And Gene Therapy Market Set for Rapid Growth and Trend by 2024-2031 Key Drivers And Analysis –Bluebird - EIN News
FY2024 Earnings Forecast for bluebird bio, Inc. Issued By Cantor Fitzgerald (NASDAQ:BLUE) - MarketBeat
7 Top Gene-Editing Stocks to Buy | Investing - U.S News & World Report Money
Patients At Last Begin Receiving Vertex-CRISPR and Bluebird Sickle Cell Gene Therapies - BioSpace
bluebird bio (NASDAQ:BLUE) Given "Neutral" Rating at Cantor Fitzgerald - MarketBeat
Bluebird Bio Inc Stock (BLUE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):